J&J joins forces with Aldeyra on anti-inflammatory diseases

27 February 2018

US biotech firm Aldeyra Therapeutics (Nasdaq: ALDX) has entered into a research agreement with Janssen Research & Development, one of the Jansen subsidiaries of healthcare giant Johnson & Johnson (NYSE: JNJ). The agreement was facilitated by Johnson & Johnson Innovation.

Under the terms of the agreement, Aldeyra will collaborate with Janssen on research activities, which will be governed by a joint scientific review committee. For a limited period, subject to certain conditions, Janssen will retain an option to negotiate an exclusive license pertaining to compounds developed during the collaboration.

No financial terms of the collaboration were disclosed, but shares of Aldeyra edged up 2.6% $7.90 in morning trading.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK